Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Arch. endocrinol. metab. (Online) ; 60(2): 108-116, Apr. 2016. tab, graf
Artigo em Inglês | LILACS | ID: lil-782152

RESUMO

ABSTRACT Objective Several formulas based in different biomarkers may be used to estimate glomerular filtration rate (GRF). However, all of them have some limitations, and it is very important to evaluate their performances in different groups of patients. Therefore, we compared GFR, as estimated by creatinine-based and cystatin C-based equations, according to albuminuria, in type 1 diabetes (T1DM), in an observational case-control study. Subjects and methods T1DM patients were classified according to albuminuria: normoalbuminuric (n = 63), microalbuminuric (n = 30), macroalbuminuric (n = 32). GFR was calculated using creatinine-based and cystatin C-based (aMDRD, CKD-EPIcr, CKD-EPIcys, MacIsaac, Tan and CKD-EPIcrcys) equations. Spearman Correlation was used to evaluate the correlation of GFR estimated by the formulas with albuminuria. ROC curves were constructed to compare AUCs of GFR estimated by equations, in reference to macroalbuminuria. Sensibility, specificity and accuracy were calculated for a cut-off < 60 mL/min/1.73 m2. Results GFR estimated by creatinine-based and cystatin C-based equations significantly differed among normoalbuminuric, microalbuminuric and macroalbuminuric patients. Spearman correlation and AUCs of GFR estimated by creatinine-based and cystatin C-based formulas were very similar to each other, though cystatin C-based equations presented better correlation with albuminuria and higher AUCs than the creatinine-based ones, and the best accuracy to detect macroalbuminuric patients. Conclusion Although GFR estimated by all creatinine-based and cystatin C-based equations permitted the differentiation between T1DM patients, according to albuminuria, cystatin C-based equations presented best accuracy to detect macroalbuminuria in T1DM patients and should be considered in the clinical routine in order to increase the possibility of early diagnostic of chronic renal disease.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Adulto Jovem , Algoritmos , Creatinina/sangue , Diabetes Mellitus Tipo 1/fisiopatologia , Diabetes Mellitus Tipo 1/sangue , Albuminúria/sangue , Cistatina C/sangue , Padrões de Referência , Valores de Referência , Ensaio de Imunoadsorção Enzimática , Biomarcadores/sangue , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Estatísticas não Paramétricas , Neuropatias Diabéticas/diagnóstico , Neuropatias Diabéticas/sangue , Insuficiência Renal Crônica/sangue , Taxa de Filtração Glomerular/fisiologia
2.
The Korean Journal of Internal Medicine ; : 579-586, 2013.
Artigo em Inglês | WPRIM | ID: wpr-175091

RESUMO

BACKGROUND/AIMS: Vitis vinifera grape seed extract (VVE) contains oligomeric proanthocyanidins that show antioxidant and free radical-scavenging activities. We evaluated VVE for its neuroprotective effect in prediabetic mice induce by a high-fat diet (HD). METHODS: Mice were divided into four groups according to VVE dose: those fed a normal diet (ND; n = 10), HD (n = 10), HD with 100 mg/kg VVE (n = 10), and HD with 250 mg/kg VVE (n = 10). After 12 weeks, immunohistochemical analyses were carried out using a polyclonal antibody against antiprotein gene product 9.5 (protein-gene-product, 9.5), and intraepidermal innervation was subsequently quantified as nerve fiber abundance per unit length of epidermis (intraepidermal nerve fiber, IENF/mm). RESULTS: Daily administration of VVE at doses of 100 or 250 mg/kg for 12 weeks protected HD mice from nerve fiber loss compared to untreated mice, as follows (IENF/mm): controls (40.95 +/- 5.40), HD (28.70 +/- 6.37), HD with 100 mg/kg (41.14 +/- 1.12), and HD with 250 mg/kg (48.98 +/- 7.01; p < 0.05, HD with VVE vs. HD). CONCLUSIONS: This study provides scientific support for the therapeutic potential of VVE in peripheral neuropathy in an HD mouse model. Our results suggest that VVE could play a role in the management of peripheral neuropathy, similar to other antioxidants known to be beneficial for diabetic peripheral neuropathy.


Assuntos
Animais , Masculino , Camundongos , Antioxidantes/farmacologia , Biomarcadores/sangue , Glicemia/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Neuropatias Diabéticas/sangue , Dieta Hiperlipídica , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Epiderme/inervação , Extrato de Sementes de Uva/farmacologia , Lipídeos/sangue , Camundongos Endogâmicos C57BL , Fármacos Neuroprotetores/farmacologia , Nervos Periféricos/efeitos dos fármacos , Fitoterapia , Plantas Medicinais , Estado Pré-Diabético/sangue , Fatores de Tempo , Vitis
3.
J. vasc. bras ; 10(4,supl.2): 1-32, 2011. ilus, tab
Artigo em Português | LILACS | ID: lil-623421

RESUMO

São apresentadas, nessa separata, as principais orientações sobre a atenção às complicações do pé diabético. A neuropatia, com suas diversas apresentações que acometem os membros inferiores dos diabéticos, as lesões da doença arterial obstrutiva periférica (DAOP), as múltiplas apresentações da infecção do pé diabético, e, principalmente, os cuidados preventivos que possam impedir o estabelecimento ou a evolução dessas complicações são tratados de forma sistemática e simplificada, visando a atenção integral desses doentes. Especial cuidado é dado às orientações diferenciadas para os diversos níveis de atenção nos serviços públicos de saúde, porta de entrada virtual de 80% dos infelizes portadores dessa complicação. São aqui apresentados modelos de atenção e sugeridos protocolos que podem contribuir para a efetiva redução do número de amputações, internações e óbitos de diabéticos com complicações nos membros inferiores.


Assuntos
Humanos , Masculino , Idoso , Doenças Vasculares Periféricas/cirurgia , Doenças Vasculares Periféricas , Doenças Vasculares Periféricas/reabilitação , Neuropatias Diabéticas/diagnóstico , Neuropatias Diabéticas/prevenção & controle , Neuropatias Diabéticas/sangue , Pé Diabético/terapia , Úlcera do Pé/patologia , Úlcera do Pé/prevenção & controle , Úlcera do Pé/terapia , Amitriptilina/administração & dosagem , Amputação Cirúrgica/reabilitação , Extremidade Inferior/patologia , Espectroscopia de Ressonância Magnética , Fatores de Risco , Tomografia Computadorizada de Emissão/métodos
4.
Arq. bras. endocrinol. metab ; 51(7): 1134-1142, out. 2007. tab, graf
Artigo em Português | LILACS | ID: lil-470078

RESUMO

A neuropatia periférica é o principal fator de risco para ulceração em pé de indivíduos diabéticos. Este estudo testou a associação de doença arterial periférica (DAP) à ulceração do pé em amostra de pacientes com neuropatia sensório-motora simétrica distal e se marcadores inflamatórios subclínicos também se associariam a esse evento. Foram avaliados 32 indivíduos diabéticos tipo 2 com exame do monofilamento de 10 g alterado, estratificados em 2 grupos segundo a história ou presença de úlcera nas extremidades inferiores. O grupo "com úlcera" (n = 18) incluiu aqueles que apresentavam úlcera ativa ou cicatrizada, ou que tiveram alguma amputação em membro inferior decorrente de complicações da úlcera. Além do exame neurológico e monofilamento, foram submetidos a bioestesiometria, avaliação vascular com Doppler e exames laboratoriais. Os grupos foram semelhantes quanto à distribuição dos sexos, média de idade e tempo de diabetes. O grupo com úlcera apresentou valores médios de altura (1,70 ± 0,06 vs. 1,63 ± 0,11 m; p = 0,044) e limiar de percepção vibratória no maléolo medial (40,9 ± 13,0 vs. 30,6 ± 12,3 V; p = 0,040) mais elevados que o sem a úlcera. Os grupos não diferiram entre si quanto à média dos marcadores inflamatórios. A resposta do reflexo patelar foi também pior no grupo com úlcera (p = 0,047), no qual se observou maior proporção de indivíduos com o índice hálux-braquial alterado (p = 0,030) quando comparado ao sem úlcera. Conclui-se que a DAP está associada à presença de úlcera (atual ou pregressa) em membros inferiores de indivíduos diabéticos neuropatas. A pesquisa de alteração de fluxo de artérias digitais de membro inferior (no hálux) contribuiu para detectar tal associação. Associação de neuropatia ulcerada a marcadores inflamatórios não foi observada, não sendo possível excluí-la devido às limitações do tamanho da amostra. Estudos prospectivos deverão examinar a sensibilidade do índice hálux-braquial...


Peripheral neuropathy is the main risk factor for foot ulceration in diabetic subjects. This study examined the association of peripheral arterial disease (PAD) with foot ulceration in a sample of diabetic subjects with peripheral neuropathy, and also if inflammatory markers would be associated with this event. We evaluated 32 type 2 diabetic individuals with abnormal 10-g monofilament exam, who were stratified in 2 groups according to history or presence of lower extremities ulcer. The group "with ulcer" (n = 18) included the ones that had active or cicatrized ulcer, or some lower-extremity amputation due to ulcer complications. In addition to the neurological examination and monofilament test, they were submitted to biothesiometry, lower extremity vascular assessment with Doppler, and laboratory determinations. No difference between the groups was found concerning sex distribution, mean age, and duration of diabetes diagnosis. The group with ulcer showed higher mean values of height (1.70 ± 0.06 vs. 1.63 ± 0.11 m, p = 0.044), vibration perception threshold measured in medial malleolli (40.9 ± 13.0 vs. 30.6 ± 12.3 V, p = 0.040) than the group without ulcer. The groups did not differ regarding the mean values of the inflammatory markers. Response to patellae reflex was worse in the group with ulcer (p = 0.047), in which a higher proportion of individuals with abnormal toe-brachial index (p = 0.030) was observed as compared to those without ulcer. We concluded that PAD is associated with the presence of ulcer in neuropathic subjects. The assessment of digital arteries flow in lower limbs (in great toe) contributed to detect such association. Association of diabetic foot ulcers and inflammatory markers was not observed, but cannot be excluded due to limitations of sample size. Prospective studies should examine the sensitivity of the toe-brachial index to identify PAD in diabetic individual at risk of ulceration.


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , /complicações , Pé Diabético/etiologia , Neuropatias Diabéticas/complicações , Doenças Vasculares Periféricas/complicações , Biomarcadores/sangue , Artéria Braquial , Proteína C-Reativa/análise , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Colesterol/sangue , /sangue , /fisiopatologia , Pé Diabético/sangue , Pé Diabético/fisiopatologia , Neuropatias Diabéticas/sangue , Neuropatias Diabéticas/fisiopatologia , Inflamação/sangue , /sangue , Exame Neurológico , Doenças Vasculares Periféricas/sangue , Doenças Vasculares Periféricas/fisiopatologia , Dedos do Pé/irrigação sanguínea , Triglicerídeos/sangue , Fator de Necrose Tumoral alfa/sangue
5.
Journal of Korean Medical Science ; : 290-294, 2006.
Artigo em Inglês | WPRIM | ID: wpr-162127

RESUMO

Diseases of the peripheral nervous system are the most prevalent in patients with end-stage renal disease (ESRD). Although increased blood levels of lead in ESRD have been reported, the role of lead remains to be elucidated. The purpose of this study was to determine the connection of blood lead concentration with peripheral nerve conduction velocity. One hundred ninety-eight healthy subjects (control group) and 68 patients with ESRD undergoing hemodialysis (ESRD group) were enrolled. Nerve conduction was measured within two hours after hemodialysis. Orthodromic sensory nerve action potentials and compound muscle action potentials were recorded on the median, ulnar, and radial nerves. Hemoglobin-corrected blood lead was significantly higher in ESRD patients than in controls (9.1+/-2.8 microgram/dL vs. 5.9+/-2.3 microgram/dL, p0.05). Our result suggested that even though the blood lead levels were high in ESRD, they were not associated with the decline of peripheral nerve function. Diabetes mellitus is a primary independent risk of neuropathy in ESRD patients.


Assuntos
Pessoa de Meia-Idade , Masculino , Humanos , Feminino , Adulto , Doenças do Sistema Nervoso Periférico/sangue , Nervos Periféricos/fisiopatologia , Condução Nervosa/fisiologia , Chumbo/sangue , Falência Renal Crônica/sangue , Neuropatias Diabéticas/sangue , Estudos de Casos e Controles , Osso e Ossos/metabolismo , Carga Corporal (Radioterapia)
6.
Artigo em Inglês | IMSEAR | ID: sea-92955

RESUMO

The present double blind randomized study was conducted on 50 subjects; 20 age and sex matched healthy controls (Group--I); 15 patients of diabetes mellitus with neuropathy who received placebo for 6 weeks (Group--IIA); and 15 patients of diabetes mellitus with neuropathy who were given supplemental zinc sulphate (660 mg) for 6 weeks (Group--IIB). Serum zinc level, fasting blood sugar (FBS) and post prandial blood sugar (PPBS) levels and motor nerve conduction velocity (MNCV) were estimated on day 0 and after 6 weeks in all subjects. Serum zinc levels were significantly low (p < 0.001) in group IIA and IIB as compared to healthy controls (Group--I) at baseline. After 6 weeks the change in pre and post therapy values of FBS, PPBS and MNCV (median and common peroneal nerve) were highly significant (P = < 0.001) for group IIB alone with insignificant change (P = > 0.05) in group IIA. No improvement (P = > 0.05) in autonomic dysfunction was observed in either groups. Therefore, oral zinc supplementation helps in achieving better glycemic control and improvement in severity of peripheral neuropathy as assessed by MNCV.


Assuntos
Administração Oral , Adulto , Idoso , Neuropatias Diabéticas/sangue , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neurônios Motores/efeitos dos fármacos , Exame Neurológico/efeitos dos fármacos , Transmissão Sináptica/efeitos dos fármacos , Zinco/sangue , Sulfato de Zinco/administração & dosagem
7.
Gac. méd. Méx ; 134(1): 85-92, ene.-feb. 1998. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-232728

RESUMO

La polineuropatía diabética es una complicación progresiva que afecta a la mayoría de los pacientes con diabetes mellitus de larga duración, y que es capaz de deteriorar gravemente su calidad de vida. En los últimos años se han desarrollado medidas terapéuticas que permiten mejorar los síntomas y la función nerviosa, y en algunos casos, prevenir y detener el daño neuronal, e incluso, favorecer la regeneración de las fibras nerviosas. La utilidad de estos tratamientos se apoya en investigaciones realizadas en animales y en seres humanos como son: a) control estricto de la glucemia (insulina), b) inhibición de la aldosa reductasa (tolrestato), c) prevención de la glucación de proteínas canino-guanidina), d) disminución de la isquemia nerviosa (vasodilatadores, ácido gamalinolénico), y e) administración de factores neurotróficos (gangliosidos). El más investigado y con evidencias más sólidas de su utilidad es el control de la glucemia. Se sugiere que el tratamiento se inicie tempranamente, pues en la neuropatía avanzada hay una severa pérdida de fibras nerviosas que dificulta la recuperación


Assuntos
Humanos , Animais , Ácido gama-Linolênico/uso terapêutico , Aldeído Redutase/antagonistas & inibidores , Glicemia/análise , Enzimas e Coenzimas , Gangliosídeos/uso terapêutico , Guanidinas/uso terapêutico , Insulina/uso terapêutico , Naftalenos/uso terapêutico , Neuropatias Diabéticas/metabolismo , Neuropatias Diabéticas/tratamento farmacológico , Neuropatias Diabéticas/sangue , Vasodilatadores/uso terapêutico
9.
El-Minia Medical Bulletin. 1993; 4 (2): 369-388
em Inglês | IMEMR | ID: emr-28040

RESUMO

The present study included 150 patients with non insulin dependent diabetes mellitus. They were 111 males and 39 females, aged from 31-66 with a mean age of 50 +/- 7.4 years. The duration of diabetes mellitus ranged from 3-25 years with a mean duration of 8.6 +/- 3.9 years. Clinical results showed that 67 cases of the 150 diabetic patients [44.7 percent] had symptomatic peripheral neuropathy. Out of them, 21 [14 percent] cases had subjective symptoms of neuropathy without objective signs and 46 cases [30.7 percent] showed symptoms and signs of diabetic polyneuropathy. Diabetic autonomic neuropathy was detected in 24 [16 percent] patients; all of them had objective neuropathy. Also diabetic cranial neuropathy was present in 2 [1.3 percent] subjects. There were positive correlations between duration of diabetes and severity of hyperglycemia as well as clinical severity; while age had statistically non significant correlation with both


Assuntos
Humanos , Masculino , Feminino , Diabetes Mellitus/complicações , Neuropatias Diabéticas/sangue , Neuropatias Diabéticas/metabolismo , Diabetes Mellitus Tipo 2
10.
JBMS-Journal of the Bahrain Medical Society. 1993; 5 (2): 68-72
em Inglês | IMEMR | ID: emr-28248

RESUMO

Seventy two Libyan diabetic patients with type II diabetes were clinically examined for the presence of secondary complications. These patients were attending the outpatient clinic of the diabetes hospital, Tripoli, libya after overnight fasting. 39% of them have eye disorders [background or proliferative retinopathy with or without cataract], 26.4% have autonomic neuropathy, 19% have vescular complications [microangiopathy or peripheral vascular disease] and 3% have nephropathy. The mean levels of fasting plasma glucose, body mass index and heart rate of these patients were 234 +/- 10 mg/di,30.7 +/- 0.7 kg/m2 and 78 +/- 1.7 beats/minute respectively. 32 patients have heart rate higher than 75 beats/min while 7 patients have lower than 65 beats/min. it is suspected that autonomic neuropathy might be the cause for these changes in the heart rate. Duration of diabetes appears to play some role in the onset and and progression of diabetic secondary complications especially in obese patients with poor metabolic control. Nephropathy and proliferative retinopathy seem to develop in the advanced stages of the disease. The responders [those with fasting plasma glucose less than 200 mg/di and Hb A1 less than 10%] have significantly lower levels of serum triglycerides, blood urea, serum creatinine and higher rate of creatinine clearance as well as lower mean/BMI score when compared with the nonresponders [those with plasma glucose levels higher than 200 mg/dl and Hb A1 more than 10%]. However, the levels of serum cholesterol of birth groups were not significantly different


Assuntos
Glicemia , Diabetes Mellitus/diagnóstico , Amputação Cirúrgica , Neuropatias Diabéticas , Líbia/epidemiologia , Neuropatias Diabéticas/sangue , Retinopatia Diabética , Prevalência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA